Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics (Nasdaq: SLN), a global clinical-stage company specializing in siRNA therapies, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12^th at 1:00 p.m. ET.

The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250305330507/en/

Inquiries:

Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc